Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Efficacy of obesity in metastatic colorectal cancer patients treated with bevacizumab-based chemotherapy combinations: A Turkish Oncology Group Study

Date

08 Oct 2016

Session

Poster Display

Presenters

Mehmet Artac

Citation

Annals of Oncology (2016) 27 (6): 149-206. 10.1093/annonc/mdw370

Authors

M. Artac1, L. Korkmaz2, H. Coskun3, F. Dane4, B. Karabulut5, M. Karaağaç2, D. Çabuk6, S. Karabulut7, F. Aykan7, H. Doruk8, N. Avci9, S. Turhal10

Author affiliations

  • 1 Medical Oncology, Necmettin Erbakan University Meram Medical Faculty, 42080 - Konya/TR
  • 2 Medical Oncology, Necmettin Erbakan University, 42080 - Konya/TR
  • 3 Medical Oncology, Akdeniz University Medical Oncology, 07058 - Antalya/TR
  • 4 Medical Oncology, Marmara University Hospital, Istanbul/TR
  • 5 Tulay Aktas Oncology, Ege University Medical School, 35100 - Izmir/TR
  • 6 Medical Oncology, Kocaeli University, Kocaeli/TR
  • 7 Medical Oncology, Istanbul University Institute of Oncology, 34093 - Istanbul/TR
  • 8 Medical Oncology, Acibadem Bursa Hospital, 16140 - Bursa/TR
  • 9 Medical Oncology, Ali Osman Sonmez Oncology Hospital Medical Oncology & Hematology Clinic, Bursa/TR
  • 10 Medical Oncology, Anadolu Health Center, Istanbul/TR
More

Resources

Background

Obesity is known as a carcinogenic factor for colorectal cancer. Interestingly, obesity is associated with increased VEGF levels. Therefore, we aimed to investigate whether obesity affects survival in metastatic colorectal cancer (mCRC) patients who treated with bevacizumab combined chemotherapies.

Methods

Five hundred and sixty three patients with mCRC who received first-line chemotherapy combination with bevacizumab were studied retrospectively. Patients were grouped as obese (BMI levels > 30) and non-obese (BMI levels 

Results

The median age of all the patients was 59 years. Non-obese group had longer PFS than obese group (P = 0.030). 2-year survival rate of non-obese group was also significantly higher (P = 0.036). In the univariate cox regression analysis ECOG ≤1, male gender, and non-obesity were the positive factors for PFS (HRs: 0.46, 0.81, and 0.75, respectively). In the multivariate analysis ECOG performance status was found as the most powerful prognostic factor for PFS (HR: 0.47, P 1 402 (85%) 72 (15%) 71 (80%) 18 (20%) 473 (84%) 90 (16%) Female 175(37%) 53 (60%) 228 (40%) Male 299 (63%) 36 (40%) 335 (60%) Metastases Liver 215 (46%) 38 (43%) 253 (45%) Multiple The other sites 147 (31%) 110 (23%) 25 (28%) 26 (29%) 172 (31%) 136 (24%) Treatments FI + BEV 308 (65%) 52 (58%) 360 (64%) FO + BEV 142 (30%) 33 (37%) 175 (31%) F + BEV 24 (5%) 4 (5%) 28 (5%) Kras status Wild 163 (81.5%) 37 (18.5%) 200 (100%) Mutant 157 (85.8%) 26 (14.2%) 175 (31%)

Conclusions

Efficacy of bevacizumab may be lower in obese patients. Prospectively designed studies for obese patients should be done to recommend the efficacy of bevacuzimab in mCRC.

Clinical trial identification

Not applicable

Legal entity responsible for the study

N/A

Funding

Turkish Oncology Group (TOG)

Disclosure

All authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings